Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0325814116
Tue, 22.06.2021
Kuros Biosciences AG
First peer-reviewed article with demonstrated efficacy in preclinical and clinical studies
Outlines ability of MagnetOs to deliver uniform, stable and reliable bone fusions
Schlieren (Zurich), Switzerland, 22, 2021 - Kuros Biosciences (SIX: KURN) today announced the publication of new data in eCM Journal, a peer-reviewed publication focusing on p [ … ]
Thu, 17.06.2021
Kuros Biosciences AG
Schlieren (Zurich), Switzerland, 17 June, 2021 - Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that high-profile surgeons will present on the STRUCTURE clinical trial with Fibrin-PTH and on preclinical and clinical data for MagnetOs bone gra [ … ]
Wed, 02.06.2021
Kuros Biosciences AG
MagnetOs U.S. Q1 sales accelerate, rising 117% over Q1 2020
European distribution network expansion ahead of schedule
Key commercial events in Australia, UK
Schlieren (Zurich), Switzerland, June 2, 2021 - Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies, today pro-vided an update on its commercial activities, wit [ … ]
Mon, 17.05.2021
Kuros Biosciences AG
* Milestone triggered by Checkmate's initiation of potential registration trial of vidutolimod (CMP-001) in
patients with anti-PD-1 refractory advanced melanoma
* Kuros stands to receive up to $49 million additional milestones plus royalties on sales
Schlieren (Zurich), Switzerland, May 17, 2021 - Kuros Biosciences ('Kuros'), a leader in [ … ]
Wed, 05.05.2021
Kuros Biosciences AG
Grant of European patent entitled 'Pharmaceutical Formulation for Use in Spinal Fusion'
Schlieren (Zurich), Switzerland, May 5, 2021 - Kuros Biosciences AG (SIX: KURN), a leader in next generation bone graft technologies, today announced that its subsidiary, Kuros Biosurgery AG, has been granted European patent EP 2686027, entitled 'Pharmaceutical [ … ]